$120.62
1.20% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US53220K5048
Symbol
LGND

Ligand Pharmaceuticals Incorporated Stock price

$120.62
+8.80 7.87% 1M
+34.22 39.61% 6M
+49.20 68.89% YTD
+61.61 104.41% 1Y
+22.21 22.57% 3Y
+52.19 76.26% 5Y
+87.69 266.34% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+1.43 1.20%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Market capitalization $2.28b
Enterprise Value $2.07b
P/E (TTM) P/E ratio 47.99
EV/FCF (TTM) EV/FCF 27.98
EV/Sales (TTM) EV/Sales 13.56
P/S ratio (TTM) P/S ratio 14.95
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth -0.76%
Revenue (TTM) Revenue $152.42m
EBIT (operating result TTM) EBIT $17.98m
Free Cash Flow (TTM) Free Cash Flow $73.86m
Cash position $219.64m
EPS (TTM) EPS $2.51
P/E forward 69.19
P/S forward 13.95
EV/Sales forward 12.65
Short interest 7.05%
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
100%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
152 152
1% 1%
100%
- Direct Costs 43 43
32% 32%
28%
110 110
21% 21%
72%
- Selling and Administrative Expenses 31 31
5% 5%
21%
- Research and Development Expense 23 23
23% 23%
15%
56 56
79% 79%
36%
- Depreciation and Amortization 38 38
1% 1%
25%
EBIT (Operating Income) EBIT 18 18
360% 360%
12%
Net Profit 45 45
175% 175%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Positive
Seeking Alpha
2 days ago
I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinforcing my confidence in the company's performance. This analysis references Q3 2024 financial results press release, earnings conference call, presentation, 10-Q, and the latest 10-K.
Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Seeking Alpha
18 days ago
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - Chief Executive Officer Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hew...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 58
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today